生物学的製剤未治療乾癬性関節炎患者におけるビメ キズマブ: 無作為化, 二重盲検, フェーズ3 試験 (BE OPTIMAL)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9
This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.
Following on from this publication, further publications will report data up to Week 52 to assess the safety and efficacy of bimekizumab in PsA.
Keywords:
